Rhythm Pharmaceuticals In...

53.52
-0.78 (-1.44%)
At close: Mar 27, 2025, 3:59 PM
-1.44%
Bid 52
Market Cap 3.38B
Revenue (ttm) 133.56M
Net Income (ttm) -268.81M
EPS (ttm) -4.34
PE Ratio (ttm) -12.33
Forward PE -23.42
Analyst Buy
Ask 58.94
Volume 400,800
Avg. Volume (20D) 514,545
Open 54.17
Previous Close 54.30
Day's Range 53.44 - 55.13
52-Week Range 35.17 - 68.58
Beta 2.30

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström sy...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2017
Employees 283
Stock Exchange NASDAQ
Ticker Symbol RYTM
Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is $70, which is an increase of 30.79% from the latest price.

Stock Forecasts

Next Earnings Release

Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+11.38%
Rhythm Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription
6 months ago
+7.37%
Rhythm Pharmaceuticals shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $64.